| dc.contributor.author | Hansen, B. | |
| dc.contributor.author | Tabak, F. | |
| dc.contributor.author | Feld, J. | |
| dc.contributor.author | Janssen, H. | |
| dc.contributor.author | Cakaloglu, Y. | |
| dc.contributor.author | Farag, M. | |
| dc.contributor.author | Campenhout, M. V. | |
| dc.contributor.author | van Boemmel, F. | |
| dc.contributor.author | Rijckborst, V. | |
| dc.contributor.author | Ferenci, P. | |
| dc.date.accessioned | 2021-03-03T14:30:09Z | |
| dc.date.available | 2021-03-03T14:30:09Z | |
| dc.identifier.citation | Farag M., Campenhout M. V. , van Boemmel F., Rijckborst V., Cakaloglu Y., Ferenci P., Tabak F., Feld J., Hansen B., Janssen H., "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B", International Liver Congress (ILC), Paris, Fransa, 11 - 15 Nisan 2018, cilt.68 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_39eec05c-760b-406f-bee6-2ec38cb2b1d8 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/42933 | |
| dc.identifier.uri | https://doi.org/10.1016/s0168-8278(18)31269-8 | |
| dc.language.iso | eng | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Gastroenteroloji-(Hepatoloji) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
| dc.title | HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B | |
| dc.type | Bildiri | |
| dc.contributor.department | University Of Toronto , , | |
| dc.identifier.volume | 68 | |
| dc.contributor.firstauthorID | 153176 | |
